Creative Biolabs announced an expansion of its liposomal formulation and encapsulation services aimed at addressing what researchers describe as the "last-mile problem" in drug delivery. Liposomes, which remain the most successful drug delivery system to date, can improve drug properties like solubility, stability, and targeted tissue distribution, but selecting appropriate lipids and achieving high encapsulation efficiency without compromising stability present significant hurdles.
The company is enhancing capabilities across multiple therapeutic classes, including proteins, peptides, small-molecule drugs, and vaccine adjuvants. For proteins and peptides, Creative Biolabs focuses on optimizing encapsulation efficiency by studying factors such as phospholipid composition, buffer concentration, incubation conditions, and drug loading. This approach aims to provide formulations that maintain biological activity while improving delivery.
Small-molecule drugs, particularly in oncology and central nervous system (CNS) applications, often face challenges like hydrophobicity, dose-limiting toxicity, and poor tissue accumulation. Liposomal encapsulation can improve solubility, reduce systemic exposure, and fine-tune biodistribution. Creative Biolabs employs both passive and active loading methods, tailored to specific compounds, and includes formulation safety evaluation services to assess biocompatibility and cytotoxicity. More details on these services are available at https://www.creative-biolabs.com/lipid-based-delivery/.
In vaccine development, liposomal adjuvants allow for the integration of immunostimulants, such as MPLA, QS-21, or TLR agonists, into customizable lipid structures. This enables more precise shaping of immune responses, aligning with the growing sophistication of vaccine design. Creative Biolabs offers a complete range of liposome-based adjuvant development services to meet the complex needs of modern vaccine research.
This expansion is important because it addresses critical bottlenecks in drug development that can delay or limit the effectiveness of new therapies. By improving liposomal formulations, the services could lead to better treatments for conditions like cancer and neurological disorders, enhance vaccine efficacy, and reduce side effects through targeted delivery. For the pharmaceutical industry, overcoming these formulation challenges may accelerate the translation of promising compounds into viable therapies, ultimately benefiting patients worldwide.
